CD47 and metabolic dysfunction-associated steatotic liver disease: To find a cure for NAFLD/NASH, Gwag et al. hypothesized that CD47-blocking antibodies may be a novel treatment option for NASH and used a human organoid model of NASH, which was more relevant and translational to humans, in which anti-CD47 antibody therapy inhibited the development of organoid fibrosis and inflammation [57].